Lilly(US:LLY) Ge Long Hui A P P·2025-09-02 08:53Group 1 - The core point of the article is that Novo Nordisk's weight loss drug Wegovy has outperformed Eli Lilly's competing drug in a real-world comparative study, significantly reducing the risk of cardiovascular events in patients without diabetes [1] - Wegovy reduces the risk of heart attack, stroke, or death by 57% in overweight and obese patients without diabetes compared to Eli Lilly's drug [1] - The study also indicates that Wegovy users have a 29% lower risk of cardiovascular events and all-cause mortality, regardless of treatment interruptions [1] Group 2 - Eli Lilly's stock price fell by 1.7% in pre-market trading following the announcement of the study results [1] - As of August 29, Eli Lilly's closing price was $732.58, with a market capitalization of $693.36 billion [1] - The stock has seen a 52-week high of $935.20 and a low of $622.41, indicating significant volatility in its market performance [1]